About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Combination Therapy may Lead to Greater Disease Burden in PAH Patients

by Sheela Philomena on October 23, 2012 at 8:42 PM
Font : A-A+

 Combination Therapy may Lead to Greater Disease Burden in PAH Patients

In patients with pulmonary arterial hypertension (PAH) combination therapy with intravenous PG12 may lead to greater disease burden, finds study.

Researchers from Massachusetts General Hospital and Novartis Pharma AG in Switzerland performed statistical tests on 446 patients with PAH, of which (a) 337 were receiving monotherapy; (b) 88 were receiving non-IV PGI2 combination therapy; and (c) 21 were receiving IV PGI2 combination therapy. Results showed that pulmonary vascular resistance, mean number of PAH-related hospitalizations, and dyspnea scores were highest in those treated with IV PGI2. This study was presented during CHEST 2012, the annual meeting of the American College of Chest Physicians, held October 20 - 25, in Atlanta, Georgia.

Advertisement

Source: Eurekalert

Advertisement
Advertisement
Advertisement

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Combination Therapy may Lead to Greater Disease Burden in PAH Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests